pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Differences in professional terms usage in advertisements by enforcement of regulations and advertising media type
| Professional terms usage | Print-based advertisements N (%) | X2 (p) | Web -based advertisements N (%) | X2 (p) | Before regulation N (%) | X2 (p) | After regulation N (%) | X2 (p) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enforcement of regulation | Enforcement of regulation | Advertising media type | Advertising media type | ||||||||||
| Before | After | Before | After | Web | Web | ||||||||
| Study objective | Yes | 18(60.0) | 23(74.2) | 1.3 (.283) | 21(70.0) | 38(82.6) | 1.6 (.262) | 18(60.0) | 21(70.0) | 0.6 (.589) | 23(74.2) | 38(82.6) | 0.7 (.403) |
| No | 12(40.0) | 8(25.8) | 9(30.0) | 8(17.4) | 12(40.0) | 9(30.0) | 8(25.8) | 8(17.4) | |||||
| Study design | Yes | 0(0.0) | 26(83.9) | 45.8 (.000) | 14(46.7) | 40(87.0) | 14.3 (.000) | 0(0.0) | 14(46.7) | 18.2 (.000) | 26(83.9) | 40(87.0) | 0.1 (.748) |
| No | 30(100.0) | 5(16.1) | 16(53.3) | 6(13.0) | 30(100.0) | 16(53.3) | 5(16.1) | 6(13.0) | |||||
| Clinical trial phase | Yes | 0(0.0) | 16(51.6) | 20.9 (.000) | 9(30.0) | 26(56.5) | 5.1 (.034) | 0(0.0) | 9(30.0) | 10.5 (.002) | 16(51.6) | 26(56.5) | 0.1 (.816) |
| No | 30(100.0) | 15(48.4) | 21(70.0) | 20(43.5) | 30(100.0) | 21(70.0) | 15(48.4) | 20(43.5) | |||||
| Study group | Yes | 0(0.0) | 8(25.8) | 8.9 (.005) | 1(3.3) | 26(56.5) | 22.4 (.000) | 0(0.0) | 1(3.3) | 1.0 (1) | 8(25.8) | 26(56.5) | 7.0 (.010) |
| No | 30(100.0) | 23(74.2) | 29(96.7) | 20(43.5) | 30(100.0) | 29(96.7) | 23(74.2) | 20(43.5) | |||||
| Eligibility | Yes | 1(3.3) | 10(32.3) | 8.6 (.006) | 3(10.0) | 20(43.5) | 9.6 (.002) | 3(10.0) | 1(3.3) | 1.0 (.612) | 10(32.3) | 20(43.5) | 0.9 (.351) |
| No | 29(96.7) | 21(67.7) | 27(90.0) | 26(32.1) | 29(96.7) | 27(90.0) | 21(67.7) | 26(56.5) | |||||
| No. of study institution | Yes | 0(0.0) | 11(35.5) | 12.9 (.000) | 3(10.0) | 17(37.0) | 6.8 (.015) | 0(0.0) | 3(10.0) | 3.1 (.237) | 11(35.5) | 17(37.0) | 0.0 (.895) |
| No | 30(100.0) | 20(64.5) | 27(90.0) | 29(63.0) | 30(100.0) | 27(90.0) | 20(64.5) | 29(63.0) | |||||
| Clinical trial process | Yes | 3(10) | 11(35.5) | 5.5 (.031) | 12(40.0) | 29(63.0) | 3.8 (.062) | 3(10.0) | 12(40.0) | 7.2 (.015) | 11(35.5) | 29(63.0) | 5.6 (.022) |
| No | 27(90.0) | 20(64.5) | 18(60.0) | 17(37.0) | 27(90.0) | 18(60.0) | 20(64.5) | 17(37.0) | |||||
| Diagnosis | Yes | 2(6.7) | 14(45.2) | 11.6 (.001) | 11(36.7) | 34(73.9) | 10.4 (.002) | 2(6.7) | 11(36.7) | 7.9 (.010) | 14(45.2) | 34(73.9) | 6.5 (.016) |
| No | 28(93.3) | 17(54.8) | 19(63.3) | 12(26.1) | 28(93.3) | 19(63.3) | 17(54.8) | 12(26.1) | |||||
| Medication | Yes | 2(6.7) | 11(35.5) | 7.5 (.011) | 6(20.0) | 24(52.2) | 7.8 (.008) | 2(6.7) | 6(20.0) | 2.3 (.254) | 11(35.5) | 24(52.2) | 2.0 (.169) |
| No | 28(93.3) | 20(64.5) | 24(80.0) | 22(47.8) | 28(93.3) | 24(80.0) | 20(64.5) | 22(25.1) | |||||
| Drug action evaluation | Yes | 0(0.0) | 1(3.2) | 0.9 (.321) | 11(36.7) | 19(41.3) | 0.1 (.811) | 0(0.0) | 11(36.7) | 13.4 (.000) | 1(3.2) | 19(41.3) | 13.9 (.000) |
| No | 30(100.0) | 30(96.8) | 19(63.3) | 27(58.7) | 30(100.0) | 19(63.3) | 30(96.8) | 27(58.7) | |||||
| Disease level | Yes | 3(10.0) | 5(16.1) | 0.5 (.478) | 1(3.3) | 5(10.9) | 1.4 (.393) | 3(10.0) | 1(3.3) | 1.0 (.612) | 5(16.1) | 5(10.9) | 0.4 (.731) |
| No | 27(90.0) | 26(83.9) | 29(96.7) | 41(89.1) | 27(90.0) | 29(96.7) | 26(83.9) | 41(89.1) | |||||
| Total | 30(100.0) | 31(100.0) | 30(100.0) | 46(100.0) | 30(100.0) | 30(100.0) | 46(100.0) | 30(100.0) | |||||